Aldara activates TLR7-independent immune defence
- PMID: 23463003
- DOI: 10.1038/ncomms2566
Aldara activates TLR7-independent immune defence
Abstract
Aldara is a cream used for topical treatment of non-melanoma skin cancer, and is thought to act through stimulation of anti-tumour immunity. The active ingredient, imiquimod, has been shown to stimulate toll-like receptor 7. Aldara also induces psoriasis-like lesions when applied to naive murine skin, and as such is used as a mouse model for psoriasis. Here we find that in naive murine skin, Aldara induces inflammation largely independently of toll-like receptor 7. Surprisingly, inflammasome activation, keratinocyte death and interleukin 1 release also occur in response to the vehicle cream in the absence of imiquimod. We show that isostearic acid, a major component of the vehicle, promotes inflammasome activation in cultured keratinocytes, and so may contribute to the observed effects of Aldara on murine skin. Aldara therefore stimulates at least two immune pathways independently, and both imiquimod and vehicle are required for a full inflammatory response. Although it remains to be tested, it is possible that imiquimod-independent effects also contribute to the therapeutic efficacy of Aldara.
Similar articles
-
[New perspective in immunotherapy: local imiquimod treatment].Orv Hetil. 2010 May 9;151(19):774-83. doi: 10.1556/OH.2010.28866. Orv Hetil. 2010. PMID: 20427260 Review. Hungarian.
-
Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.J Transl Med. 2007 Jan 26;5:7. doi: 10.1186/1479-5876-5-7. J Transl Med. 2007. PMID: 17257431 Free PMC article. Clinical Trial.
-
Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.J Cutan Pathol. 2005 Apr;32(4):257-62. doi: 10.1111/j.0303-6987.2005.00297.x. J Cutan Pathol. 2005. PMID: 15769273
-
Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.J Immunother. 2011 Apr;34(3):264-9. doi: 10.1097/CJI.0b013e318209eed4. J Immunother. 2011. PMID: 21389872 Free PMC article.
-
Beyond a decade of 5% imiquimod topical therapy.J Drugs Dermatol. 2009 May;8(5):467-74. J Drugs Dermatol. 2009. PMID: 19537370 Review.
Cited by
-
The NLRP1 inflammasome in skin diseases.Front Immunol. 2023 Feb 23;14:1111611. doi: 10.3389/fimmu.2023.1111611. eCollection 2023. Front Immunol. 2023. PMID: 36911693 Free PMC article. Review.
-
Alleviation of imiquimod-induced psoriasis-like symptoms in Rorα-deficient mouse skin.BMB Rep. 2023 May;56(5):296-301. doi: 10.5483/BMBRep.2022-0169. BMB Rep. 2023. PMID: 36698281 Free PMC article.
-
Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions.Immunity. 2014 Jun 19;40(6):989-1001. doi: 10.1016/j.immuni.2014.04.019. Epub 2014 Jun 5. Immunity. 2014. PMID: 24909886 Free PMC article.
-
JNK1 Signaling Downstream of the EGFR Pathway Contributes to Aldara®-Induced Skin Inflammation.Front Immunol. 2021 Feb 5;11:604785. doi: 10.3389/fimmu.2020.604785. eCollection 2020. Front Immunol. 2021. PMID: 33613525 Free PMC article.
-
The role of dendritic cells in autoimmunity.Nat Rev Immunol. 2013 Aug;13(8):566-77. doi: 10.1038/nri3477. Epub 2013 Jul 5. Nat Rev Immunol. 2013. PMID: 23827956 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous